Voxvoganan

Voxvoganan (LTX-109), a topical antimicrobial, is highly effective against S. aureus with a MIC range of 2 to 4 μg/mL. Voxvoganan can be used for the research of bacterial skin infections, fungal infections and nasal decolonisation of MRSA^[1][2]. In Vitro: Voxvoganan (LTX-109) is an investigational antimicrobial agent with a membrane-lysing mechanism of action, based on the biological principle of innate immune effectors, lytic peptides. Voxvoganan has a rapid bactericidal lytic activity. Voxvoganan demonstrates in vitro bactericidal activity against a number of S. aureus isolates resistant to several classes of antimicrobial agents evaluated in this study^[2].
Voxvoganan (LTX-109) is a broad-spectrum, fast-acting bactericidal antimicrobial agent that binds to negatively charged membrane components on the bacterial cell wall, which leads to membrane disruption and cell lysis. Voxvoganan is a first-in-class chemically synthesized, small peptide drug that is stable against protease degradation. Topical application of Voxvoganan has a good safety profile and a low bioavailability. Voxvoganan demonstrates good activity against Staphylococcus aureus strains that are susceptible and resistant to mupirocin^[3].